# US 2017/0283774 A1 · Methods for efficient derivation of human motor neurons from diverse spinal regions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283774 A1
- Document ID: US20170283774A1
- Status: Published application
- Kind: A1
- Application number: 15/475,831
- Filed: 2017-03-31
- Published: 2017-10-05
- Earliest claimed: 2016-04-01
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Ethan Scott Lippmann; Neha Sehgal; Randolph Scott Ashton
- Web page: https://patentgrep.com/patent/US20170283774A1

## CPC

- C12N 5/0619: {Neurons}
- C12N 5/0623: {Stem cells}
- C12N 2500/38: Vitamins
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/02: from embryonic cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are chemically defined, adherent culture protocols for generating functional motor neurons characteristic of diverse hindbrain and spinal cord regions, with high efficiency.

## Claims

### Claim 1

A method for generating motor neuron progenitor cells, comprising the steps of:
i. transiently exposing SOX2− and Brachyury+ neuromesodermal progenitor cells cultured in a neural differentiation base medium that comprises FGF and a first concentration of a Wnt/β-catenin signaling pathway agonist to a second higher concentration of the agonist until NKX6.1+ ventral progenitor cells are obtained; and
ii. culturing the NKX6.1+ ventral progenitor cells in the neural differentiation base medium comprising a retinoid and at least one sonic hedgehog (SHH) signaling pathway agonist in the absence of the Wnt agonist until OLIG2+, NKX6.1+, and PAX6+ motor neuron progenitor cells are obtained.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neuromesodermal progenitor cells are exposed to the second higher concentration of the Wnt/β-catenin signaling pathway agonist for about 6 hours following about 4 days in culture in the neural differentiation base medium.

### Claim 3 (depends on 1)

The method of claim 1, wherein the Wnt/β-catenin signaling pathway agonist is CHIR99021, and wherein the first concentration is about 3μM and the second higher concentration is in the range of about 6-9 μM.

### Claim 4 (depends on 1)

The method of claim 1, wherein the neuromesodermal progenitor cells are exposed to the higher concentration of the Wnt agonist for about 6 hours.

### Claim 5 (depends on 1)

The method of claim 1, wherein NKX6.1+ ventral progenitor cells have a cervical identity or a hindbrain identity.

### Claim 6 (depends on 3)

The method of claim 3, wherein the NKX6.1+ ventral progenitor cells having a cervical identity are generated with at least about 90% efficiency from the neuromesodermal progenitor cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein OLIG2+, NKX6.1+, and PAX6+ motor neuron progenitor cells are generated with at least about 80% efficiency from the NKX6.1+ ventral progenitor cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the Wnt/β-catenin signaling pathway agonist is selected from the group consisting of Wnt-3a and a glycogen synthase kinase 3 (GSK3) inhibitor, wherein the GSK3 inhibitor is selected from the group consisting of CHIR99021, CHIR98014, BIO-acetoxime, BIO, LiC1, SB216763, SB415286, AR A014418, 1-Azakenpaullone, and Bis-7-indolylmaleimide.

### Claim 9 (depends on 1)

The method of claim 1, wherein the SHH signaling pathway agonist is selected from the group consisting of purmorphamine (PM), SHH, and a combination thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the neuromesodermal progenitor cells are cultured at a cell density sufficiently high to maintain a confluent but not tightly packed cell monolayer.

### Claim 11 (depends on 10)

The method of claim 10, wherein the NKX6.1+ ventral progenitor cells have a thoracic identity.

### Claim 12 (depends on 10)

The method of claim 10, wherein the medium in which the NKX6.1+ ventral progenitor cells are cultured further comprises a Growth Differentiation Factor and an inhibitor of BMP signaling.

### Claim 13 (depends on 12)

The method of claim 12, wherein the inhibitor of BMP signaling is dorsomorphin.

### Claim 14 (depends on 12)

The method of claim 12, wherein the motor neuron progenitor cells have a lumbar identity.

### Claim 15 (depends on 1)

The method of claim 1, wherein the neuromesodermal progenitor cells are obtained by culturing human pluripotent stem cells in the presence of the Wnt/β-catenin signaling pathway agonist and FGF in the neural differentiation base medium until the neuromesodermal progenitor cells are obtained.

### Claim 16 (depends on 1)

The method of claim 1, wherein the neural differentiation base medium is selected from the group consisting of E4, E5, and E6 medium.

### Claim 17 (depends on 1)

The method of claim 1, wherein the retinoid is retinoic acid.

### Claim 18 (depends on 1)

A method of generating post-mitotic motor neurons having a specified spinal cord regional identity, comprising exposing the motor neuron progenitor cells obtained according to the method of claim 1 to a retinoid and to at least one SHH signaling pathway agonist in the neural differentiation base medium, and optionally exposing the motor neuron progenitor cells to dorsomorphin (DM) in the base medium, until SMI32+, ISL1+, and HB9+ post-mitotic motor neurons having a specified spinal cord regional identity are obtained.

### Claim 19 (depends on 18)

The method of claim 18, wherein the post-mitotic motor neurons are generated from the motor neuron progenitor cells at an efficiency of between about 55% and about 70%.

### Claim 20 (depends on 18)

The method of claim 18, wherein the at least one SHH signaling pathway agonist is selected from the group consisting of purmorphamine (PM), SHH, and a combination thereof.

### Claim 21 (depends on 17)

The method of claim 17, wherein the motor neuron progenitor cells are exposed to the retinoid and to the SHH agonist for about 10 to about 14 days.

### Claim 22 (depends on 18)

The method of claim 18, wherein the retinoid is retinoic acid.

### Claim 23 (depends on 18)

The method of claim 18, wherein the motor neuron progenitor cells are obtained from neuromesodermal progenitor cells, wherein the neuromesodermal progenitor cells are obtained by culturing human pluripotent stem cells in the presence of the Wnt agonist and FGF in the neural differentiation base medium until the neuromesodermal progenitor cells are obtained.
